$2.61
$140.2 M
BLPH Mkt cap, 14-Jun-2018Bellerophon Therapeutics Net income (Q1, 2018)4.1 M
Bellerophon Therapeutics EBIT (Q1, 2018)-8.5 M
Bellerophon Therapeutics Cash, 31-Mar-201828.4 M
Bellerophon Therapeutics Financials
Bellerophon Therapeutics Income Statement
Annual
| USD | FY, 2016 |
|---|---|
R&D expense | 5.1 m |
General and administrative expense | 2.2 m |
Operating expense total | 7.3 m |
EBIT | (7.3 m) |
Income tax expense | (438 k) |
Net Income | (7.4 m) |
Quarterly
| USD | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q1, 2018 |
|---|---|---|---|---|---|---|---|---|
R&D expense | 9.5 m | 8.4 m | 7.1 m | 5.1 m | 4 m | 2.5 m | 3.3 m | 6.4 m |
General and administrative expense | 4.6 m | 3.4 m | 4.3 m | 2 m | 1.2 m | 1.7 m | 1.4 m | 2.1 m |
Operating expense total | 14.1 m | 11.9 m | 11.4 m | 7.1 m | 5.2 m | 4.2 m | 4.8 m | 8.5 m |
EBIT | (12.9 m) | (11.6 m) | (11.2 m) | (7.1 m) | (5.2 m) | (4.2 m) | (4.8 m) | (8.5 m) |
Interest income | 19 k | 27 k | 27 k | 30 k | 22 k | 22 k | 27 k | 99 k |
Income tax expense | 5.4 m | |||||||
Net Income | (12.9 m) | (11.6 m) | (11.1 m) | (7.1 m) | (5.1 m) | (4.2 m) | (19.1 m) | 4.1 m |
Bellerophon Therapeutics Balance Sheet
Annual
| USD | FY, 2016 |
|---|---|
Cash | 14.5 m |
Current Assets | 26.5 m |
PP&E | 1.4 m |
Total Assets | 29.7 m |
Accounts Payable | 2.8 m |
Current Liabilities | 6.5 m |
Total Liabilities | 11.7 m |
Additional Paid-in Capital | 142.2 m |
Retained Earnings | (124.5 m) |
Total Equity | 18 m |
Financial Leverage | 1.7 x |
Quarterly
| USD | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q1, 2018 |
|---|---|---|---|---|---|---|---|---|
Cash | 62.9 m | 48.5 m | 23.9 m | 1.3 m | 1.3 m | 3.9 m | 13.5 m | 28.4 m |
Current Assets | 73.6 m | 60.9 m | 46.9 m | 23.1 m | 18.6 m | 17.5 m | 23.2 m | 34.8 m |
PP&E | 1.6 m | 1.5 m | 1.8 m | 1.7 m | 1.6 m | 1.5 m | 1.3 m | 935 k |
Total Assets | 75.2 m | 62.4 m | 49.2 m | 31.2 m | 26.3 m | 22.8 m | 25.8 m | 35.9 m |
Accounts Payable | 659 k | 966 k | 934 k | 641 k | 2 m | 2.2 m | 3.9 m | 4.6 m |
Current Liabilities | 12.8 m | 11.2 m | 8.6 m | 7.3 m | 6.2 m | 4.8 m | 6.1 m | 8.4 m |
Total Liabilities | 33.7 m | |||||||
Additional Paid-in Capital | 131.5 m | 132.8 m | 134.9 m | 144.1 m | 176.9 m | |||
Retained Earnings | (67.1 m) | (78.7 m) | (89.9 m) | (107.7 m) | (112.9 m) | (117.1 m) | (143.6 m) | (175.2 m) |
Total Equity | 23.9 m | 20.1 m | 18 m | 800 k | 2.2 m | |||
Financial Leverage | 1.3 x | 1.3 x | 1.3 x | 32.2 x | 16.2 x |
Bellerophon Therapeutics Cash Flow
Annual
| USD | FY, 2016 |
|---|---|
Net Income | (23.8 m) |
Depreciation and Amortization | (400 k) |
Cash From Operating Activities | (17.2 m) |
Cash From Investing Activities | 12.2 m |
Cash From Financing Activities | 13.2 m |
Free Cash Flow | (17.2 m) |
Bellerophon Therapeutics Ratios
| USD | Y, 2018 |
|---|---|
Financial Leverage | 16.2 x |
Report incorrect company information
